• Total Revenue: Achieved record revenues of $675 million in 2023.

• GAAP Net Income: Reported full-year GAAP net income of $42 million.

• Adjusted EBITDA: Delivered $214.5 million in adjusted EBITDA.

• EXPAREL Sales: EXPAREL net product sales reached $538.1 million.

• Operational Efficiency: Reduced total operating expenses to $587.3 million in 2023 from $606.8 million in 2022.

• Stock Performance: Basic and diluted weighted average shares of common stock stood at 46.4 million and 52.1 million respectively.

• 2024 Financial Guidance: Provided full-year 2024 revenue guidance of $680 million to $705 million.

• Warning! GuruFocus has detected 4 Warning Sign with PCRX.

On February 29, 2024, Pacira BioSciences Inc (NASDAQ:PCRX) released its 8-K filing, announcing its financial results for the fourth quarter and full-year of 2023. The company, a leader in non-opioid pain management and regenerative health solutions, reported record revenues of $675 million for the year, a modest increase from the previous year's $666.8 million. The full-year GAAP net income stood at $42 million, with an adjusted EBITDA of $214.5 million.

Pacira BioSciences Inc is known for its flagship product, EXPAREL, which utilizes its proprietary DepoFoam technology to deliver pain medication over an extended period. This innovative approach has now reached over 14 million patients, marking a significant milestone for the company.

The company's financial achievements are particularly noteworthy in the context of the drug manufacturing industry, where innovation and the ability to scale production efficiently can significantly impact profitability. The approval of a new 200-liter EXPAREL manufacturing suite by the FDA is expected to enhance gross margins over time, reflecting the company's commitment to operational excellence and growth.

Financial Performance Analysis

The year 2023 saw a nominal increase in EXPAREL net product sales, which amounted to $538.1 million, despite having two fewer selling days compared to 2022. ZILRETTA net product sales also grew by 5% to $111.1 million. The company's iovera net product sales witnessed a significant 29% increase, reaching $19.7 million for the year.

Operating expenses for the year were reduced to $587.3 million from $606.8 million in 2022, reflecting the company's efforts to streamline operations and manage costs effectively. Research and development expenses decreased to $76.3 million in 2023 from $84.8 million in the previous year, while selling, general, and administrative expenses increased slightly to $269.4 million.